← GENELUX Corp (GNLX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
GENELUX Corp (GNLX)
Pharmaceutical Preparations · market cap $114M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Genelux Corporation (GNLX) is a late clinical-stage oncolytic viral immunotherapy company with a market cap of ~$136M and a lead asset, Olvi-Vec (olvimulogene nanivacirepvec), that completed its Phase 3 trial in platinum-resistant ovarian cancer as of June 2026. The company is pre-revenue with only $9.3M cash on hand, implying a runway of roughly 4–5 months absent additional financing. The stock trades at ~$3.03 against analyst price targets ranging from $10 to $31, reflecting a wide dispersion of views on the binary outcome ahead.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-02-15 (est.)Phase 2 · Platinum chemotherapy: carboplatin or cisplatinimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GL-ONC1 | Phase 2 | Peritoneal Carcinomatosis |
| olvimulogene nanivacirepvec | Phase 3 | Platinum-resistant Ovarian Cancer |
| Platinum chemotherapy: carboplatin or cisplatin | Phase 2 | Advanced Non-squamous Non-small-cell Lung Cancer |
| Olvi-Vec | Phase 2 | Ovarian Cancer |
Price & technical context
3-month
-15.7%
6-month
-1.6%
12-month
-40.0%
52-wk range
$2.30–$8.24
vs 50-day MA
-4.9%
vs 200-day MA
-11.5%
Realized vol
83.8%
Max drawdown
-72.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GNLX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.